31,021 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Teza Capital Management LLC

Teza Capital Management LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,021 shares of the biotechnology company's stock, valued at approximately $1,033,000.

A number of other institutional investors also recently modified their holdings of EXEL. Invesco Ltd. increased its position in shares of Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Norges Bank bought a new position in shares of Exelixis in the fourth quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Exelixis by 330.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock valued at $82,730,000 after buying an additional 1,907,167 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Exelixis by 104.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock worth $105,208,000 after acquiring an additional 1,613,482 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Exelixis by 25.7% in the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock valued at $132,101,000 after purchasing an additional 810,857 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

Shares of EXEL traded down $0.86 during trading hours on Thursday, hitting $42.86. The stock had a trading volume of 2,977,285 shares, compared to its average volume of 2,292,372. The firm has a market capitalization of $11.69 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 1.13 and a beta of 0.25. The firm has a 50-day moving average price of $37.68 and a 200 day moving average price of $36.03. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $48.85.

Insiders Place Their Bets

In related news, Director George Poste sold 20,634 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $45.99, for a total value of $948,957.66. Following the transaction, the director now directly owns 169,020 shares of the company's stock, valued at $7,773,229.80. This trade represents a 10.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 29,314 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This represents a 3.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 520,942 shares of company stock worth $22,930,002 in the last 90 days. Corporate insiders own 2.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EXEL shares. Barclays raised their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a report on Thursday, February 13th. UBS Group reiterated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Piper Sandler lifted their price objective on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Finally, Citigroup boosted their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Exelixis currently has an average rating of "Moderate Buy" and an average target price of $38.94.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.